Benzinga's Top #PreMarket Losers

slipped 22.36% to $34.75 in pre-market trading after the company delayed filing its new drug application for Nuplazid treatment for psychosis related to Parkinson's disease.

fell 15.64% to $31.50 in pre-market trading. Inogen reaffirmed its forecast for 2015 and announced the Audit Committee investigation into accounting matters. The company also postponed its Q4 earnings Release and conference call.

shares fell 13.30% to $17.80 in pre-market trading after the company posted a wider-than-expected operating loss for its fourth quarter.

shares dropped 7.86% to $18.75 in pre-market. Krispy Kreme reported in-line earnings for the fourth-quarter, but the company's revenue missed analysts' estimates.

shares declined 5.12% to $44.50 in pre-market trading after posting its first quarterly report following its initial public offering.